

Construction of Artificial Viral Capsids Encapsulating Short DNAs via Disulfide Bonds and Controlled Release of DNAs by Reduction

Yoko Nakamura,¹ Hiroshi Inaba,^{1,2} and Kazunori Matsuura*^{1,2}

¹ Department of Chemistry and Biotechnology, Graduate School of Engineering, Tottori University, 4-101 Koyama-minami, Tottori 680-8552

² Center for Research on Green Sustainable Chemistry, Tottori University, 4-101 Koyama-minami, Tottori 680-8552

E-mail: ma2ra-k@tottori-u.ac.jp

1 To construct an artificial viral capsid encapsulated
2 short single-stranded DNA, a β -annulus peptide conjugated
3 with ssDNA through a disulfide bond at the N-terminus
4 (DNA-SS- β -Annulus) was synthesized. The DNA-SS- β -
5 Annulus conjugate self-assembled into spherical structures
6 ranging in the size of 36–60 nm. ssDNA was released from
7 the capsids via the reduction of disulfide bonds.
8 **Keywords:** Artificial viral capsid, Nanocarrier, DNA,
9 **Disulfide bond**


10 Spherical viral capsids are natural supramolecular
11 nanocapsules with icosahedral symmetry, which are formed
12 via self-assembly from capsid proteins. They have attracted
13 significant attention as scaffolding materials, which can act
14 as drug carriers, vaccine platforms, and nanoreactors
15 because of their specific properties, such as discrete
16 nanospace, good cell-transfection ability, and
17 biodegradability.¹ Particularly, the encapsulation of nucleic
18 acids in the discrete nanospace of spherical viral capsids has
19 made the improved resistance of nucleic acids in cells
20 against enzymatic degradation possible, which can be
21 applied as a nanocarrier for the delivery of nucleic acid
22 drugs.^{1c,2}

23 In biological systems, disulfide bonds comprising
24 cysteines play an important role in the stability of the three-
25 dimensional structures of proteins, and in the control of
26 certain protein functions³, which are susceptible to the redox
27 environment in the cytoplasm. The reductive cleavage of
28 disulfide bonds is utilized to release drugs in the cytoplasm
29 from nanomaterials, such as polymeric micelles.⁴ However,
30 to the best of our knowledge there are fewer reports on the
31 controlled-release of guest molecules by reductive cleavage
32 of disulfide bonds when viral capsids are used as scaffold
33 materials.⁵

34 We have previously demonstrated that a synthetic 24-
35 mer β -annulus peptide fragment (INHVGTTGGA
36 IMAVAVTRQLVGS), which is a structural motif of the
37 internal skeleton of the tomato bushy stunt virus, self-
38 assembled into hollow nanocapsules (artificial viral capsid)
39 ranging in the size of 30–50 nm in water.^{6,7} The pH-
40 dependent zeta-potentials of the artificial viral capsid
41 indicate that the C-terminus of the peptide is directed toward
42 the exterior surface, while the N-terminus is directed toward
43 the interior.⁸ By utilizing this feature, we have reported that
44 the C-terminus modification allowed the decoration of the
45 exterior surface of the artificial viral capsid with gold
46 nanoparticles,^{9a} coiled-coil spikes,^{9b} and ssDNAs.^{9c}
47 Moreover, we have demonstrated the encapsulation of

48 anionic dyes, a long DNA (M13 phage DNA),⁸ and the
49 preparation of quantum dots (CdTe)^{10a} via electrostatic
50 interaction in the cationic interior of the artificial viral
51 capsid. Furthermore, by employing the proper N-terminus
52 modification, fluorescent ZnO nanoparticles^{10b} and His-
53 tagged GFP^{10c} have been encapsulated in the artificial viral
54 capsid.

55 Here, we report the construction of an artificial viral
56 capsid **encapsulating** single-stranded DNA (ssDNA) via the
57 self-assembly of the β -annulus peptide modified with
58 ssDNA at the N-terminal through a disulfide bond, wherein
59 the ssDNA was directed to the interior (Figure 1). **Linking**
60 **of β -annulus peptide with DNA via disulfide bond ensures**
61 **the encapsulation of short DNAs, which has been difficult to**
62 **achieve so far.** The controlled-release of the ssDNA from




63 the capsid can be achieved by reductive cleavage of
64 disulfide bonds **under intracellular reducing environment**.

65
66 **Figure 1.** Schematic illustration of the ssDNA encapsulated in
67 an artificial viral capsid through a disulfide bond, and the
68 release of ssDNA by reduction using DTT.

69
70
71 A 23-mer ssDNA (TCTACAAAGGGAAGCCC
72 TTTCTG) bearing an amino group via a hexamethylene
73 chain at the 5' end was reacted with 3-(2-pyridyldithio)
74 propionic acid *N*-hydroxysuccinimide ester (SPDP) to
75 obtain a ssDNA bearing pyridyldisulfide group at the 5' end
76 (PySS-DNA). A β -annulus peptide containing Cys at the N-
77 terminus (CINHVGTTGGAIMAVAVTRQLVGS: Cys- β -
78 Annulus) was synthesized using a standard Fmoc-protected

1 solid-phase method. A subsequent disulfide-exchange
 2 reaction of PySS-DNA with the excess amount of thiol at
 3 the N-terminus of the Cys- β -Annulus afforded the β -
 4 annulus peptide to be modified with the ssDNA via a
 5 disulfide bond (DNA-SS- β -Annulus). In the reversed-phase
 6 HPLC chart, the reaction mixture displayed one main peak
 7 at 24.9 min, which was different from the retention time of
 8 SPDP, ssDNA, and PySS-DNA (Figure 2A). The purified
 9 product was confirmed to be DNA-SS- β -Annulus using
 10 MALDI-TOF-MS ($m/z = 9692 [M]^+$) (Figure 2B). The
 11 dynamic light scattering (DLS) of 50 μM DNA-SS- β -
 12 Annulus in sodium phosphate buffer (pH 7.1) exhibited the
 13 formation of 48 ± 12 -nm assemblies (Figure 2C). The
 14 transmission electron microscopy (TEM) image of the
 15 aqueous solution of DNA-SS- β -Annulus also exhibited the
 16 formation of spherical assemblies of approximately 50 nm
 17 in diameter (Figure 2D). The structure of the assembly of
 18 DNA-SS- β -Annulus is comparable to that of the unmodified
 19 artificial viral capsid,⁶ indicating that the modification of




20 ssDNAs at the N-terminus of the β -annulus peptide
 21 minimally affect the capsid structure.

22
 23 **Figure 2.** (A) Reversed-phase HPLC chart of (a) SPDP, (b)
 24 ssDNA, and (c) PySS-DNA detected at 260 nm, eluted with a
 25 linear gradient of $\text{CH}_3\text{CN} / 0.1 \text{ M NH}_4\text{HCO}_2$ aq (0 / 100 to 100
 26 / 0 over 95 min). (d) DNA-SS- β -Annulus detected at 260 nm,
 27 eluted with a linear gradient of $\text{CH}_3\text{CN} / 0.1 \text{ M NH}_4\text{HCO}_2$ aq
 28 (10 / 90 to 100 / 0 over 95 min). (B) MALDI-TOF-MS of the
 29 purified DNA-SS- β -Annulus (matrix: 3-HPA). (C) Size
 30 distributions obtained from DLS analysis for 50 μM DNA-SS-
 31 β -Annulus in 10 mM sodium phosphate buffer (pH 7.1). (D)
 32 TEM image of 50 μM DNA-SS- β -Annulus in 10 mM sodium
 33 phosphate buffer stained with 2% phosphotungstic acid.

34
 35
 36 We have previously reported that artificial viral
 37 capsids decorated with ssDNAs on the exterior surface were

38 self-assembled from β -annulus peptides modified with
 39 ssDNA (dA₂₀ and dT₂₀).^{9c} The ssDNA-modified peptides
 40 formed spherical assemblies with diameters of 46–150 nm,
 41 although aggregations were observed at higher
 42 concentrations (>50 μM). Conversely, the concentration
 43 dependence of the size distribution in DLS measurement
 44 indicated that DNA-SS- β -Annulus formed assemblies with
 45 sizes ranging from 30 to 50 nm at a concentration of 25–100
 46 μM (Figure 3A). Since highly charged DNA can be
 47 condensed by multivalent counterions,¹¹ it is likely that the
 48 artificial viral capsid encapsulated ssDNA is stabilized by
 49 electrostatic condensation between the ssDNA and the
 50 cationic interior of the capsid.




51
 52 **Figure 3.** Concentration dependence of size distribution (A)
 53 and scattering intensity (B) obtained from DLS for the aqueous
 54 solution of DNA-SS- β -Annulus in 10 mM sodium phosphate
 55 buffer (pH 7.1) at 25°C.

56
 57
 58 The concentration dependence of the scattering
 59 intensity of the aqueous solution of DNA-SS- β -Annulus
 60 revealed that the critical aggregation concentration (CAC)
 61 of DNA-SS- β -Annulus was 3.1 μM (Figure 3B). DLS
 62 analysis and TEM images of DNA-SS- β -Annulus in water
 63 at various pH values indicated that the peptide could stably
 64 self-assemble in the pH range of 4–11, whereas the peptide
 65 aggregated at pH 2 (Figure S1).

66 To confirm the controlled-release of the encapsulated
 67 ssDNA by reductive cleavage of disulfide bonds, the
 68 artificial viral capsid was reacted with 10 mM dithiothreitol
 69 (DTT) for 2 h in 10 mM sodium phosphate buffer (pH 7.1).
 70 A new peak appeared in the reversed-phase HPLC chart
 71 after the reaction with DTT, and the peak derived from the
 72 DNA-SS- β -Annulus disappeared (Figure 4A). The MALDI-
 73 TOF-MS of the reaction mixture revealed the existence of
 74 Cys- β -Annulus ($m/z = 2409$) and ssDNA bearing a thiol
 75 group ($m/z = 7291$) (Figure 4B). DLS analysis and TEM
 76 images of the reaction mixture revealed that the spherical
 77 structures were disrupted (Figure 4C and 4D). The
 78 unstructured aggregates observed on TEM images (Figure
 79 4D) were also observed in the aqueous solution of Cys- β -
 80 Annulus without ssDNA (Figure S2). These results
 81 indicated that the ssDNA encapsulated in the artificial viral
 82 capsid was successfully released by reductive cleavage of
 83 disulfide bonds, which was accompanied by the destruction
 84 of the capsid. **It is probable that the destruction of the capsid
 85 might be caused by cancellation of electrostatic
 86 condensation between the ssDNA and the cationic interior
 87 of the capsid.**

1 We also attempted to release ssDNAs from artificial
 2 viral capsids using 10 mM reduced glutathione (GSH),
 3 which is the most abundant substance in cells, that act as a
 4 reducing agent in 10 mM sodium phosphate buffer (pH 7.1)
 5 (Figure S3). The peak area derived from the DNA-SS- β -
 6 Annulus decreased to 63% after a 2-h reaction with GSH,
 7 and to 11% after 18 h of reaction in the reversed-phase
 8 HPLC chart (Figure S3). The MALDI-TOF-MS of the
 9 reaction mixture showed the existence of substances
 10 produced by the disulfide-exchange reaction (Figure S3).
 11



12 **Figure 4.** The reduction of DNA-SS- β -Annulus ([DNA-SS- β -
 13 Annulus] = 50 μ M, [DTT] = 10 mM) in 10 mM sodium
 14 phosphate buffer (pH 7.1) at 25°C. (A) Reversed-phase HPLC
 15 chart of DNA-SS- β -Annulus (a) before addition of DTT and (b)
 16 2 h after addition of DTT detected at 260 nm, eluted with a
 17 linear gradient of CH₃CN / 0.1 M NH₄HCO₂ aq (100 / 0 to 0 /
 18 100 over 70 min), (B) MALDI-TOF-MS (matrix: 3-HPA), (C)
 19 DLS, and (D) TEM image for the solution of 50 μ M DNA-SS-
 20 β -Annulus 2 h after the addition of 10 mM DTT.

21
 22
 23 DLS analysis and TEM images of the mixture showed
 24 the co-existence of intact artificial viral capsids and
 25 collapsed aggregates (Figure S3). Therefore, ssDNAs may
 26 have been partially released due to incomplete reduction
 27 using 10 mM GSH. **The slower reduction rate of GSH**
 28 **compared to that of DTT might be caused by smaller redox**
 29 **potential of GSH (-0.24 V) than that of DTT (-0.33 V).**

30
 31 In conclusion, the results of this study demonstrated
 32 that artificial viral capsid encapsulated ssDNA was self-
 33 assembled from β -annulus peptide modified with ssDNA at
 34 the N-terminus through a disulfide bond. Further, it was
 35 observed that the reductive cleavage of the disulfide bond of
 36 the artificial viral capsid by DTT or GSH caused the
 37 controlled-release of ssDNA with the destruction of the
 38 capsid. We envision that this system can be applied to drug
 39 delivery systems for short chain nucleic acid drugs, such as
 40 siRNA and antisense DNA. **When the reduction condition is**
properly selected, it will be possible to release DNAs

41 **without the destruction of capsid. If it is possible, further**
 42 **applications can be developed such as reversible**
 43 **modification of thiol-modified materials in artificial viral**
 44 **capsid.**

45
 46 This work was supported by a Grant-in-Aid for
 47 Scientific Research on Innovative Areas “Chemistry for
 48 Multimolecular Crowding Biosystems” (JSPS KAKENHI
 49 Grant No. JP18H04558).
 50

51 References and Notes

- 52
 53 1 Steinmentz, *Nanomedicine*. **2010**, 6, 634. c) A. M. Wen, N. F.
 54 Steinmetz, *Chem. Soc. Rev.* **2016**, 45, 4074. d) S.-Y. Lee, J.-S.
 55 Lim, M. T. Harris, *Biotechnol. Bioeng.* **2012**, 109, 16. e) Z. Liu, J.
 56 Qiao, Z. Niu, Q. Wang, *Chem. Soc. Rev.* **2012**, 41, 6178. f) Y.
 57 Ma, R. J. M. Nolte, J. J. L. M. Cornelissen, *Adv. Drug Deliv. Rev.*
 58 **2012**, 64, 811. g) R. L. Garcea, L. Gissmann, *Curr. Opin.*
 59 *Biotechnol.* **2004**, 15, 513. h) E. M. Plummer, M. Manchester,
 60 *Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.* **2011**, 3, 174.
 61 2 a) J. Kong, Y. Wang, J. Zhang, E. Qi, R. Su, Z. He, *Angew.*
 62 *Chem. Int. Ed.* **2018**, 57, 1. b) Y. Azuma, T. G. W. Edwardson, N.
 63 Terasaka, D. Hilvert. *J. Am. Chem. Soc.* **2018**, 140, 566. c) A.
 64 Samante, I. L. Medintz, *Nanoscale*. **2016**, 8, 9037.
 65 3 a) W. J. Wedemeyer, E. Welker, M. Narayan, H. A. Scheraga,
 66 *Biochemistry*. **2000**, 39, 4207. b) K. J. Woycechowsky, R. T.
 67 Raines, *Curr. Opin. Chem. Biol.* **2000**, 4, 533. c) H. Kadokura, F.
 68 Katzen, J. Beckwith, *Annu. Rev. Biochem.* **2003**, 72, 111.
 69 4 a) K. Matsuura, K. Tochio, K. Watanabe, N. Kimizuka, *Chem.*
 70 *Lett.* **2011**, 40, 711. b) C. Baek, T.-L. Ha, E. Kim, S. W. Jeong, S.
 71 G. Lee, H.-C. Kim, *Polymers*. **2015**, 7, 2245. c) S. Matsumoto, R.
 72 J. Christie, N. Nishiyama, K. Miyata, A. Ishii, M. Oba, H.
 73 Koyama, Y. Yamasaki, K. Kataoka, *Biomacromolecules*. **2009**,
 74 10, 119. d) T. Ooya, H. S. Choi, A. Yamashita, N. Yui, Y.
 75 Sugaya, A. Kano, A. Maruyama, H. Akita, R. Ito, K. Kogure, H.
 76 Harashima, *J. Am. Chem. Soc.* **2006**, 128, 3852.
 77 5 a) K. Niikura, N. Sugimura, Y. Musashi, S. Mikuni, Y. Matsuo,
 78 S. Kobayashi, K. Nagakawa, S. Takahara, C. Takeushi, H. Sawa,
 79 M. Kinjo, K. Ijio, *Mol. BioSyst.* **2013**, 9, 501. b) Y. Wu, L.
 80 Zhang, C. Cui, S. Cansiz, H. Liang, C. Wu, I.-T. Teng, W. Chen,
 81 Y. Liu, W. Hou, X. Zhang, W. Tan, *J. Am. Chem. Soc.* **2018**, 140,
 82 2.
 83 6 K. Matsuura, K. Watanabe, T. Matsuzaki, K. Sakurai, N.
 84 Kimizuka, *Angew. Chem. Int. Ed.* **2010**, 49, 9662.
 85 7 K. Matsuura, *Chem. Commun.* **2018**, 54, 8944.
 86 8 K. Matsuura, K. Watanabe, Y. Matsushita, N. Kimizuka, *Polym.*
 87 *J.* **2013**, 45, 529.
 88 9 a) K. Matsuura, G. Ueno, S. Fujita, *Polym. J.* **2015**, 47, 146. b) S.
 89 Fujita, K. Matsuura, *Org. Biomol. Chem.* **2017**, 15, 5070. c) Y.
 90 Nakamura, S. Yamada, S. Nishikawa, K. Matsuura, *J. Pept. Sci.*
 91 **2017**, 23, 636.
 92 10 a) S. Fujita, K. Matsuura, *Chem. Lett.* **2016**, 45, 922. b) S. Fujita,
 93 K. Matsuura, *Nanomaterials*. **2014**, 4, 778. c) K. Matsuura, T.
 94 Nakamura, K. Watanabe, T. Noguchi, K. Minamihata, N.
 95 Kamiya, N. Kimizuka, *Org. Biomol. Chem.* **2016**, 14, 7869.
 96 11 M. Kuron, A. Arnold, *Eur. Phys. J. E.* **2015**, 38, 20.

Graphical Abstract

Textual Information

A brief abstract
(required)

We synthesized a β -annulus peptide (DNA-SS- β -Annulus) modified with short single-stranded DNA via a disulfide bond at the N-terminus to construct an artificial viral capsid encapsulating ssDNAs. The DNA-SS- β -Annulus conjugate self-assembled into a spherical structure with the size of 36 - 60 nm. The viral capsids caused the release of ssDNAs via reduction of the disulfide bonds.

Title(required)

Construction of Artificial Viral Capsids Encapsulating Short DNAs via Disulfide Bonds by Self-assembly

Authors'
Names(required)

Yoko Nakamura, Hiroshi Inaba, and Kazunori Matsuura

Graphical Information

